Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has ...

Dr. Meghraj Ingle reminds nonalcoholic fatty liver disease (NAFLD), which got no noticeable symptoms in its early stages, can ...

Nat Clin Pract Gastroenterol Hepatol. 2009;6(1):18-19. Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the Western world. NAFLD is associated with chronic ...

"My interest in NAFLD started with a close friend's grandfather when he was diagnosed with liver cancer. He had never even ...

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

Loneliness and social isolation have been linked to an elevated risk of non-alcoholic fatty liver disease (NAFLD), according to a groundbreaking study conducted by researchers from Central South ...

Non-alcoholic fatty liver disease (NAFLD) is regarded as a manifestation of metabolic syndrome in the liver. This investigation was initiated to determine whether NAFLD has a relationship to ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

Drawing on years of experience studying non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD), SMC has created the world’s first preclinical model with a type 2 diabetic ...

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...